Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05148156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Jun 2027 → Sep 2027
See other at-risk trials from Northwell Health

Record History

  1. Recruitment resumed after suspension Start date: Dec 15, 2021 to Feb 11, 2026 · Primary completion pushed from Jun 2027 to Sep 2027 · Eligibility criteria expanded, about 22 words · 2 more Show 5 more changesShow less
    • Start date: Dec 15, 2021 to Feb 11, 2026
    • Primary completion pushed from Jun 2027 to Sep 2027
    • Eligibility criteria expanded, about 22 words
    • Site details revised
    • Publications: details revised at 9 of 10 entries
  2. Primary completion date: Jan 2026 to Jun 2027 Completion date: Mar 2026 to Mar 2028v8 Show 1 more changeShow less
    • Completion date: Mar 2026 to Mar 2028
  3. Primary completion date: Dec 2024 to Jan 2026 Completion date: Dec 2024 to Mar 2026 · Eligibility criteria revised · Study site revisedv7 Show 3 more changesShow less
    • Completion date: Dec 2024 to Mar 2026
    • Eligibility criteria revised
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  4. Lead sponsor: Weill Medical College of Cornell University to Northwell Healthv6
  5. Trial status: Active, Not Recruiting to Suspended Sponsor's reason: Principal Investigator changing locations.v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Dec 2022 to Dec 2024 Trial status: Recruiting to Active, Not Recruiting · Completion date: Jun 2023 to Dec 2024 · Study description expanded, about 103 words · 2 morev4 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Jun 2023 to Dec 2024
    • Study description expanded, about 103 words
    • Site details revised
    • Study title expanded, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: May 2022 to Dec 2022 Completion date: May 2022 to Jun 2023 · Site contact updatedv3 Show 2 more changesShow less
    • Completion date: May 2022 to Jun 2023
    • Site contact updated
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2021 to Dec 15, 2021 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2021 to Dec 15, 2021
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia. The investigator hypothesizes that Urolift, which represents a novel minimally invasive therapy, may reduce acute and long-term urinary toxicity and side effects of radiation therapy (SBRT).
Trial Details
NCT Number NCT05148156
Lead Sponsor Northwell Health
Collaborators: NeoTract, Inc., Teleflex
Conditions Benign Prostatic Hyperplasia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov